Happy David  Walters net worth and biography

Happy Walters Biography and Net Worth

Director of Hyperion DeFi

Happy Walters serves on the Board of Directors at Hyperion DeFi, bringing over 25 years of leadership experience across blockchain, fintech, sports, and entertainment. He is the Founder and CEO of Blue Horizon Capital and a board member at Immutable Holdings. Walters has a proven track record in scaling innovative companies and investing in frontier technologies, including early positions in Hedera Hashgraph and Axelar Networks. His expertise in governance and strategic growth makes him a key contributor to Hyperion DeFi’s mission to advance decentralized finance solutions.

What is Happy David Walters' net worth?

The estimated net worth of Happy David Walters is at least $449.40 thousand as of December 17th, 2025. Mr. Walters owns 111,930 shares of Hyperion DeFi stock worth more than $449,399 as of September 22nd. This net worth estimate does not reflect any other assets that Mr. Walters may own. Learn More about Happy David Walters' net worth.

How do I contact Happy David Walters?

The corporate mailing address for Mr. Walters and other Hyperion DeFi executives is 3090 Nowitzki Way, Suite 300, Dallas, TX, 75219. Hyperion DeFi can also be reached via phone at (833) 393-6684 and via email at [email protected]. Learn More on Happy David Walters' contact information.

Has Happy David Walters been buying or selling shares of Hyperion DeFi?

Happy David Walters has not been actively trading shares of Hyperion DeFi during the last quarter. Most recently, on Wednesday, December 17th, Happy David Walters bought 61,930 shares of Hyperion DeFi stock. The stock was acquired at an average cost of $3.02 per share, with a total value of $187,028.60. Following the completion of the transaction, the director now directly owns 111,930 shares of the company's stock, valued at $338,028.60. Learn More on Happy David Walters' trading history.

Who are Hyperion DeFi's active insiders?

Hyperion DeFi's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), David Knox (CFO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), Michael Rowe (COO), Ellen Strahlman (Director), and Happy Walters (Director). Learn More on Hyperion DeFi's active insiders.

Are insiders buying or selling shares of Hyperion DeFi?

In the last twelve months, Hyperion DeFi insiders bought shares 11 times. They purchased a total of 197,204 shares worth more than $641,026.94. The most recent insider tranaction occured on June, 2nd when insider Hyunsu Jung bought 1,000 shares worth more than $3,660.00. Insiders at Hyperion DeFi own 7.5% of the company. Learn More about insider trades at Hyperion DeFi.

Information on this page was last updated on 6/2/2026.

Happy David Walters Insider Trading History at Hyperion DeFi

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/17/2025Buy61,930$3.02$187,028.60111,930View SEC Filing Icon  
See Full Table

Happy David Walters Buying and Selling Activity at Hyperion DeFi

This chart shows Happy David Walters's buying and selling at Hyperion DeFi by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Hyperion DeFi Company Overview

Hyperion DeFi logo
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $4.00
Low: $3.83
High: $4.05

50 Day Range

MA: $3.03
Low: $2.34
High: $3.92

2 Week Range

Now: $4.00
Low: $2.34
High: $11.89

Volume

506,151 shs

Average Volume

468,653 shs

Market Capitalization

$62.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.53